The class III variant of the epidermal growth factor receptor (EGFRvIII): characterization and utilization as an immunotherapeutic target.

Published

Journal Article (Review)

Any immunotherapeutic approach to cancer cell eradication is based upon the specific recognition of neoplastic cells and the sparing of surrounding normal tissue; perhaps nowhere is this distinction more important than within the central nervous system, due to the diffuse infiltrative nature of primary glial tumor cell growth. Whether ultimate effect moieties are immunoglobulins, fragments and/or their constructs with drugs, toxins, radionuclides, or immune cells, the specificity of effector: cell surface marker is crucial. This review describes the identification, immunologic characterization, and biologic behavior of a transmembrane tumor-specific altered growth factor receptor molecule which may well serve as a mediator of multiple immunotherapeutic approaches: the class III variant of the epidermal growth factor receptor, EGFRvIII.

Full Text

Duke Authors

Cited Authors

  • Wikstrand, CJ; Reist, CJ; Archer, GE; Zalutsky, MR; Bigner, DD

Published Date

  • April 1998

Published In

Volume / Issue

  • 4 / 2

Start / End Page

  • 148 - 158

PubMed ID

  • 9584952

Pubmed Central ID

  • 9584952

International Standard Serial Number (ISSN)

  • 1355-0284

Digital Object Identifier (DOI)

  • 10.3109/13550289809114515

Language

  • eng

Conference Location

  • United States